Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801R59" target="_blank" >RIV/61988987:17110/17:A1801R59 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/17:10363892 RIV/00843989:_____/17:E0106165 RIV/00064165:_____/17:10363892
Result on the web
<a href="http://dx.doi.org/10.1038/bcj.2017.31" target="_blank" >http://dx.doi.org/10.1038/bcj.2017.31</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/bcj.2017.31" target="_blank" >10.1038/bcj.2017.31</a>
Alternative languages
Result language
angličtina
Original language name
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment
Original language description
Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomidedexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib-lenalidomide-dexamethasone (KRd) was based on results from the randomized, phase 3 study ASPIRE (NCT01080391), which showed KRd significantly improved progression-free survival (PFS) vs Rd (median 26.3 vs 17.6 months; hazard ratio (HR) = 0.690; P = 0.0001). This subgroup analysis of ASPIRE evaluated KRd vs Rd by number of previous lines of therapy and previous exposure to bortezomib, thalidomide or lenalidomide. Treatment with KRd led to a 12-month improvement in median PFS vs Rd after first relapse (HR 0.713) and a 9-month improvement after >= 2 previous lines of therapy (HR 0.720). Treatment with KRd led to an approximate 8-month improvement vs Rd in median PFS in bortezomib-exposed patients (HR 0.699), a 15-month improvement in thalidomide-exposed patients (HR 0.587) and a 5-month improvement in lenalidomideexposed patients (HR 0.796). Objective response and complete response or better rates were higher with KRd vs Rd, irrespective of previous treatment. KRd had a favorable benefit-risk profile and should be considered an appropriate treatment option for patients with 1 or >= 2 previous lines of therapy and those previously exposed to bortezomib, thalidomide or lenalidomide.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
BLOOD CANCER JOURNAL
ISSN
2044-5385
e-ISSN
—
Volume of the periodical
7
Issue of the periodical within the volume
duben 2017
Country of publishing house
GB - UNITED KINGDOM
Number of pages
9
Pages from-to
—
UT code for WoS article
000401102500003
EID of the result in the Scopus database
2-s2.0-85024486755